We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers incl... Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company. The Company is engaged in the advancement of treatment applications for cancers throughout the body. It is a producer of Cesium-131 brachytherapy seeds. These seeds are designed to treat a variety of cancers including prostate cancer, head and neck, lung and brain. The Company has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also engaged in the development of imaging diagnostics (Pb-203 (Lead-203)). The Company¿s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions. Show more
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.17 | 11.8055555556 | 1.44 | 1.77 | 1.3597 | 5157803 | 1.62033579 | CS |
4 | 0.36 | 28.8 | 1.25 | 1.77 | 1.15 | 6495750 | 1.47978423 | CS |
12 | 0.787 | 95.6257594168 | 0.823 | 1.77 | 0.7178 | 4086622 | 1.27260402 | CS |
26 | 1.3489 | 516.621983914 | 0.2611 | 1.77 | 0.2201 | 2551690 | 1.08225022 | CS |
52 | 1.09 | 209.615384615 | 0.52 | 1.77 | 0.205 | 1602406 | 0.93810463 | CS |
156 | 1.2337 | 327.850119585 | 0.3763 | 1.77 | 0.205 | 1467488 | 0.9113423 | CS |
260 | 1.2337 | 327.850119585 | 0.3763 | 1.77 | 0.205 | 1467488 | 0.9113423 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions